Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.

@article{Yin2006BayesianDI,
  title={Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.},
  author={Guosheng Yin and Yisheng Li and Yuan Ji},
  journal={Biometrics},
  year={2006},
  volume={62 3},
  pages={777-84}
}
A Bayesian adaptive design is proposed for dose-finding in phase I/II clinical trials to incorporate the bivariate outcomes, toxicity and efficacy, of a new treatment. Without specifying any parametric functional form for the drug dose-response curve, we jointly model the bivariate binary data to account for the correlation between toxicity and efficacy. After observing all the responses of each cohort of patients, the dosage for the next cohort is escalated, deescalated, or unchanged according… CONTINUE READING